View all 2016 ophthalmology-specific measures in the Physician Quality Reporting System. Download the 2016 PQRS Changes (PDF) document.
Note: Effective Oct. 1, measures with an * are impacted by new ICD-10 codes which are not included in the measure specifications and therefore, any patient visits with the new diagnosis codes are not counted towards the measure.
Measure 1*— Diabetes Hemoglobin A1c Poor Control (PDF)
Measure 12*— Primary Open Angle Glaucoma (POAG) Optic Nerve Evaluation (PDF)
Measure 14*— Age-Related Macular Degeneration (AMD): Dilated Macular Examination (PDF)
Measure 18*— (NQF# 0088): Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy (PDF)
Measure 19*— Diabetic Retinopathy Communication with the Physician Managing On-going Diabetes Care (PDF)
Measure 110— (NQF 0041) Preventive Care and Screening Influenza Immunization (PDF)
Measure 111— (NQF 0043) Pneumonia Vaccination Status for Older Adults (PDF)
Measure 117*— Diabetes Eye Exam (PDF)
Measure 130— Documentation of Current Medications in the Medical Record (PDF)
Measure 131— Pain Assessment and Follow-Up (PDF)
Measure 137— Melanoma Continuity of Care – Recall System (PDF)
Measure 138— Melanoma Coordination of Care (PDF)
Measure 140*— Age-Related Macular Degeneration (AMD) Counseling on Antioxidant Supplement (PDF)
Measure 141*— Primary Open-Angle Glaucoma (POAG) Reduction of IOP by 15 percent or Documentation of a Plan of Care (PDF)
Measure 191— Cataracts 2040 or Better Visual Acuity within 90 Days Following Cataract Surgery (PDF)
Measure 192— Cataracts Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures (PDF)
Measure 224— Melanoma Overutilization of Imaging Studies in Melanoma (PDF)
Measure 226— Preventive Care and Screening Tobacco Use Screening and Cessation Intervention (PDF)
Measure 236— (NQF 0018) Controlling High Blood Pressure (PDF)
Measure 238— Use of High-Risk Medications in the Elderly (PDF)
Measure 265— Biopsy Follow-Up (PDF)
Measure 303— Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery (PDF)
Measure 304— Patient Satisfaction within 90 Days Following Cataract Surgery (PDF)
Measure 317— Preventive Care and Screening Screening for High Blood Pressure and Follow-Up Documented (PDF)
Measure 318— (NQF 0101) Falls Screening for Future Fall Risk (PDF)
Measure 374— Closing the Referral Loop: Receipt of Specialist Report (PDF)
Measure 384*— Adult Primary Rhegmatogenous Retinal Detachment No Return to the Operating Room Within 90 Days of Surgery (PDF)
Measure 385*— Adult Primary Rhegmatogenous Retinal Detachment Surgery Visual Acuity Improvement Within 90 Days of Surgery (PDF)
Measure 388— Cataract Surgery with Intra-Operative Complications -Unplanned Rupture of Posterior Capsule requiring unplanned vitrectomy (PDF)
Measure 389— Cataract Surgery Difference Between Planned and Final Refraction (PDF)
Measure 397— Melanoma Reporting (PDF)
Measure 402— Tobacco Use and Help with Quitting Among Adolescents (PDF)
QCDR Measures Reporting
For 2016, the Academy proposes the following measures for manual reporting only through the IRIS Registry as a qualified clinical data registry. Physicians who cannot identify nine individual PQRS measures for 2016 can make up the difference by reporting additional measures from the list below. Learn more about PQRS reporting options.
The following 20 measures may be reported through IRIS® Registry only.
- You do not need an electronic health record system.
- When registering with the IRIS Registry, choose the option for non-EHR reporting and choose individual measure reporting.
- Identify nine measures across three quality domains for at least 50 percent of total qualifying patients seen between Jan. 1 and Dec. 31, 2016.
- You must choose additional measures from the individual measures reporting option as part of your nine measures to satisfy the requirement for reporting across three quality domains. You must report each measure for at least 50 percent of all patients you see this calendar year for whom the measure applies -- not just patients with Medicare Part B, Medicare as a Secondary or Railroad Medicare insurance, .
- All the 20 qualified clinical data registry (“QCDR”) measures fall into the Effective Clinical Care domain. Physicians need to ensure their measure selection meets the quality domain requirement. All the new QCDR measures are outcome measures, with the exception of AAO-9. As such, they count toward the two outcome measure requirement for QCDR reporting.
- Rather than reporting PQRS category II codes, physicians will report either: performance met, performance exclusion, or performance not met into the IRIS Registry Web portal.
- The IRIS Registry Web portal will include a measure-selection page that will identify the quality domain and measure type.
QCDR Measure: AAO-1: Corneal Graft Surgery, Post-operative improvement in visual acuity to 20/40 or greater (PDF)
Percentage of corneal graft surgery patients with a visual acuity of 20/40 or greater at 90 days after surgery
QCDR Measure: AAO-2: Glaucoma – Intraocular Pressure (IOP) Reduction (PDF)
Percentage of glaucoma patient visits where their IOP was below a threshold level based on the severity of their diagnosis
QCDR Measure: AAO-3: Glaucoma – Visual Field Progression in Glaucoma (PDF)
Percentage of eyes, in patients with a diagnosis of glaucoma, with a mean deviation loss of more than 3dB from their baseline value
QCDR Measure: AAO-4: Glaucoma – Intraocular Pressure Reduction Following Laser Trabeculoplasty (PDF)
Percentage of patients underwent laser trabeculoplasty who had IOP reduced by 20% from their pretreatment level
QCDR Measure: AAO-5: Surgery for Acquired Involutional Ptosis: Patients with an improvement of marginal reflex distance (MRD) (PDF)
Percentage of surgical ptosis patients with an improvement of MRD postoperatively
QCDR Measure: AAO-6: Acquired Involutional Entropion: Normalized lid position after surgical repair (PDF)
Percentage of surgical entropion patients with a postoperative normalized lid position
QCDR Measure: AAO-7: Amblyopia: Interocular visual acuity (PDF)
Percentage of newly diagnosed amblyopic patients with a corrected interocular VA difference of 2 or fewer lines (< 0.23 logMAR) within 12 to 18 months of first diagnosis
QCDR Measure: AAO-8: Surgical Esotropia: Postoperative alignment (PDF)
Percentage of surgical esotropia patients with a postoperative alignment of 15 PD or less
QCDR Measure: AAO-9: Diabetic Retinopathy: Documentation of the Presence or Absence of Macular Edema and the Level of Severity of Retinopathy (PDF)
Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed which included documentation of the level of severity of retinopathy and the presence or absence of macular edema during one or more office visits within 12 months
QCDR Measure: AAO-10: Exudative Age-Related Macular Degeneration: Loss of Visual Acuity (PDF)
Percentage of patients with a diagnosis of exudative age-related macular degeneration, being treated with anti-VEGF agents, with of loss of less than 0.3 logMar of visual acuity within the past 12 months
QCDR Measure: AAO-11: Nonexudative Age-Related Macular Degeneration: Loss of Visual Acuity (PDF)
Percentage of patients with a diagnosis of nonexudative age-related macular degeneration and taking AREDS supplements with of loss of less than 0.3 logMar of visual acuity within the past 12 months
QCDR Measure: AAO-12: Age-Related Macular Degeneration: Disease Progression (PDF)
Percentage of patients with nonexudative age-related macular degeneration progressing to exudative age-related macular degeneration over the past 12 months
QCDR Measure: AAO-13: Diabetic Macular Edema: Loss of Visual Acuity (PDF)
Percentage of patients with a diagnosis of diabetic macular edema with of loss of less than 0.3 logMar of visual acuity within the past 12 months
QCDR Measure: AAO-16: Acute Anterior Uveitis: Post-treatment visual acuity (PDF)
Percentage of acute anterior uveitis patients with a post-treatment best corrected visual acuity of 20/40 or greater OR patients whose visual acuity had returned to their baseline value prior to onset of uveitis
QCDR Measure: AAO-17: Acute Anterior Uveitis: Post-treatment Grade 0 anterior chamber cells (PDF)
Percentage of patients with acute anterior uveitis post-treatment with Grade 0 anterior chamber cells QCDR Measure: AAO-18: Chronic Anterior Uveitis: Post-treatment visual acuity Percentage of chronic anterior uveitis patients with a post-treatment best corrected visual acuity of 20/40 or greater OR patients whose visual acuity had returned to their baseline value prior to onset of uveitis
QCDR Measure: AAO-19: Chronic Anterior Uveitis: Post-treatment Grade 0 anterior chamber cells (PDF)
Percentage of patients with chronic anterior uveitis post-treatment with Grade 0 anterior chamber cells
QCDR Measure: AAO-20: Idiopathic Intracranial Hypertension: No worsening or improvement of mean deviation (PDF — updated May 2016)
Percentage of patients with no worsening of perimetric mean deviation by >3dB at 6 months or improvement in mean deviation at 6 months
QCDR Measure: AAO-21: Ocular Myasthenia Gravis: Improvement of ocular deviation or absence or diplopia or functional improvement (PDF — updated May 2016)
Percentage of patients with a diagnosis of ocular myasthenia gravis who had an improvement of ocular deviation OR were absent of diplopia in primary gaze OR had functional improvement of ptosis 6 months after initial treatment
QCDR Measure: AAO-22: Giant Cell Arteritis: Absence of fellow eye involvement after corticosteroid treatment (PDF — updated May 2016)
Percentage of patients without fellow eye involvement 1-26 weeks after initiating corticosteroids in patients with unilateral visual loss